bioRxiv : the preprint server for biology
August 13, 2026
David S Jacobs, Alejandro Torrado Pacheco, Randall J. Olson et al.
preprint
Emerging clinical research with psilocybin highlights the value of the psychedelic experience on successful treatment of a multitude of psychiatric disorders. While the psychedelic trip or clinical support procedures cannot be modeled in rodents, neural processes critical to meta-learning and flexible modification of previously learned strategies can be quantified during psilocybin exposure....
medRxiv
August 12, 2026
Scott M. Thompson, Devin P. Effinger, Andrew M Novick et al.
preprint
Abstract Oregon (OR) and Colorado (CO) were the first states to enact regulations for provision of psilocybin with support of licensed ‘facilitators.’ As more states and countries adopt similar policies, informed public policy decisions require that client characteristics and rationale for using psilocybin, psilocybin dosing practices, mental health outcomes, and adverse events are understood....
Drugs and Drug Candidates
August 12, 2026
M. Salgaço, D. D. Farias, Mariela Zucolo de Souza et al.
Background/Objectives: This study investigated the effects of a single dose of psilocybin-containing Psilocybe cubensis extract on gut microbiota composition, microbial metabolism, and intestinal immune-related responses. Methods: A single dose of P. cubensis extract (35 mg/L) was subjected to colonic fermentation using the SHIME® model inoculated with fecal microbiota from individuals with...
bioRxiv
August 12, 2026
preprint
Investigating the Effects of Psilocybin on Cognitive Flexibility in Touchscreen and Naturalistic Variations of the Probabilistic Reversal Learning Task
Journal of Clinical Medicine
August 12, 2026
Teodora Anghel, Adriana Cojocaru, Lavinia Hogea et al.
Background/Objectives: Psilocybin-assisted therapy has progressed from early proof-of-concept work to a substantially expanded evidence base, with four pivotal studies published in 2025–2026 that were not incorporated into earlier reviews. This review synthesizes the pharmacological and neurobiological foundations of psilocybin and appraises clinical evidence across major depressive disorder...
Acta Crystallographica Section C Structural Chemistry
August 7, 2026
Sonya K. Emmett, Lee Cameron, Mark Hestermann et al.
The crystal structure of the known low-temperature anhydrous phase of psilocybin {3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate, C12H17N2O4P} is reported. While the structure was previously characterized using powder X-ray diffraction, this study describes the first determination via single-crystal X-ray diffraction. High-resolution structural models were obtained both before...
CNS Drugs
August 7, 2026
Chiranth Bhagavan, Olivia Carter, Glenn Nielsen et al.
BACKGROUND: Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study examined the feasibility and safety of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers....
Nature Medicine
August 6, 2026
James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al.
1 citation
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
The Brown University Psychopharmacology Update
August 3, 2026
Individuals with cocaine use disorder who received a single dose of psilocybin combined with psychotherapy showed greater reductions in cocaine use relative to active placebo with psychotherapy, a randomized trial has found. No serious adverse events were reported during the trial.
British Journal of Mental Health Nursing
August 2, 2026
Rachel Sinclair
Depression remains a significant public health concern worldwide and many individuals do not achieve adequate symptom relief from conventional treatments such as antidepressants and psychological therapies. Interest has therefore increased in alternative interventions, including psilocybin microdosing. This article aimed to critically review the current evidence regarding the use of psilocybin...
Journal of Pain
August 1, 2026
Jon G Dean, Ethan Hurwitz, T. Furnish et al.
Phantom limb pain (PLP) is a refractory condition defined by pain experienced in a missing limb. Psilocybin, a classical serotonergic psychedelic drug, can alleviate various treatment-resistant disorders but has scantly been investigated for chronic pain. This placebo-controlled, double-blind, randomized clinical pilot trial (NCT05224336) tested the feasibility, tolerability, and preliminary...
Journal of Pain and Symptom Management
August 1, 2026
Daniel A. Schaefer, Manish Agrawal, Emanuele Mazzola et al.
CONTEXT Psilocybin-assisted therapy has demonstrated rapid antidepressant effects in patients with cancer, but most trials have excluded individuals receiving active systemic anticancer treatment, limiting safety data in this population. OBJECTIVES To compare the efficacy and safety of psilocybin-assisted therapy in patients receiving versus not receiving concurrent systemic anticancer...
European Journal of Pharmacology
August 1, 2026
Erik Kaadt, Rolf Søkilde, Hanne Demant Garling et al.
Novel treatment strategies are needed to address treatment resistance and delayed onset of action in psychiatry. Psilocybin has shown promise as a treatment for major depressive disorder, but the molecular changes associated with its effects remain incompletely understood. In parallel, microRNAs (miRNAs) have been implicated in depression and in responses to antidepressant interventions. Here,...
EBioMedicine
August 1, 2026
The use of psilocybin for treatment-resistant depression (TRD) is moving towards clinical use, and two unresolved questions will shape what comes next: how large and durable the benefit is, and what produces it? The strongest peer-reviewed efficacy signal is a phase 2b trial, in which one dose of synthetic psilocybin with psychological support approximately doubled the depression-score...
Journal of Affective Disorders
August 1, 2026
Taro Kishi, Kenji Sakuma, Masakazu Hatano et al.
This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups....
Journal of Affective Disorders
August 1, 2026
Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al.
2 citations
The contribution of patient support to psilocybin's antidepressant effects remains uncertain. Relationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and EBI) and clinical outcomes (Montgomery-Åsberg Depression...
Hearing research
August 1, 2026
Shuhan Lu, Zhixin Zhang, Xinmiao Xue et al.
Subjective tinnitus is a common auditory disorder characterised by the subjective perception of noise in the absence of external sound sources. Its prevalence has been rising annually due to noise exposure, medication misuse, and population ageing. Current tinnitus treatments employ antidepressants, anticonvulsants, and vasodilators, yet most demonstrate limited efficacy with significant side...
Communications medicine
July 30, 2026
Stacey B. Armstrong, Adam W. Levin, Nathan D. Sepeda et al.
Psilocybin-assisted therapy (PAT) shows promise for treating PTSD in adults but hasn't been studied in U.S. military Veterans, who face higher symptom severity and suicide risk. This open-label pilot trial evaluated the safety and feasibility of PAT in Veterans with severe, treatment-resistant PTSD. The clinical trial was pre-registered at ClinicalTrials.gov (NCT05554094). The eligibility...
Authorea Preprints
July 30, 2026
preprint
Beyond psilocybin: Do magic mushroom preparations contain other compounds with pharmacological effects?
Frontiers in Psychiatry
July 29, 2026
Caitlyn Hanna Sams, Jasmine Davis, Anuradha Ramdas et al.
We report two case studies that examine the therapeutic potential of structured psilocybin-containing mushroom biomass regimens administered within a clinical framework, evaluating their impact on mental health outcomes as well as associated somatic symptoms. Two patients underwent the De La Haye Psilocybin Treatment Protocol (DPTP), which integrates micro- and high-doses (combined psilocybin...